Targeting the tumor stroma in cancer therapy

Current Pharmaceutical Biotechnology

Volumn 10, Issue 2, 2009, Pages 185-191

  Anton, Kevin ^a   Glod, John ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BEVACIZUMAB; COLONY STIMULATING FACTOR 1; DNA VACCINE; IMATINIB; MATRIX METALLOPROTEINASE; PACLITAXEL; SEMAXANIB; ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; BREAST CANCER; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER INVASION; CANCER RESISTANCE; CANCER THERAPY; COMBINATION CHEMOTHERAPY; CONNECTIVE TISSUE TUMOR; DRUG POTENTIATION; DRUG RESISTANCE; FIBROBLAST; HUMAN; MESENCHYMAL STEM CELL; METASTASIS; MONOTHERAPY; NONHUMAN; OVARY CARCINOMA; PERICYTE; PROTEIN EXPRESSION; REVIEW; STELLATE CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR STROMA; ANIMAL; CONNECTIVE TISSUE; DRUG EFFECT; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CONNECTIVE TISSUE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 65549114653     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920109787315088     Document Type: Review

References (98)

1. Suggitt, M. and Bibby, M.C. (2005) 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin. Cancer Res., 11(3), 971-981.
2. Folkman J. (1974) Tumor angiogensis: role in regulation of tumor growth. Symp. Soc. Dev. Biol., 30(0), 43-52.
3. Folkman J. (1975) Tumor angiogenesis: a possible control point in tumor growth. Ann. Intern. Med., 82(1), 96-100.
4. Paget, S. (1889) The distribution of secondary growths in cancer of the breast. Lancet, 1, 571-573.
5. De Wever, O. and Mareel M. (2003) Role of tissue stroma in cancer cell invasion. J. Pathol., 200(4), 429-447.
6. Chang, C. and Werb, Z. (2001) The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol., 11(11), S37-43.
7. Rossi, M.L.; Hughes, J.T.; Esiri, M.M.; Coakham, H.B. and Brownell, D.B. Immunohistological study of mononuclear cell infiltrate in malignant gliomas. (1987) Acta Neuropathol., 74(3), 269-277.
8. Frei, K.; Piani, D.; Malipiero, U.V.; Van Meir, E.; de Tribolet, N. and Fontana, A. (1992) Granulocyte-macrophage colonystimulating factor (GM-CSF) production by glioblastoma cells. Despite the presence of inducing signals GM-CSF is not expressed in vivo. J. Immunol., 148(10), 3140-3146.
9. O'Sullivan, C. and Lewis, C.E. (1994) Tumour-associated leucocytes: friends or foes in breast carcinoma. J. Pathol., 172(3), 229-235.
10. Göttlinger, H.G.; Rieber, P.; Gokel, J.M.; Lohe, K.J. and Riethmüller, G. (1985) Infiltrating mononuclear cells in human breast carcinoma: predominance of T4+ monocytic cells in the tumor stroma. Int. J. Cancer, 35(2), 199-205.
11. Nakagawa, H.; Liyanarachchi, S.; Davuluri, R.V.; Auer, H.; Martin, E.W Jr.; de la Chapelle, A. and Frankel, W.L. (2004) Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene, 23(44), 7366-77.
12. Hwang, R.F.; Moore, T.; Arumugam, T.; Ramachandran, V.; Amos, K.D.; Rivera, A.; Ji, B.; Evans, D.B. and Logsdon, C.D. (2008) Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res., 68(3), 918-926.
13. Nishie, A.; Ono, M.; Shono, T.; Fukushi, J.; Otsubo, M.; Onoue, H.; Ito, Y.; Inamura, T.; Ikezaki, K.; Fukui, M.; Iwaki, T. and Kuwano, M. (1999) Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin. Cancer Res., 5(5), 1107-1113.
14. Gouon-Evans, V.; Lin, E.Y. and Pollard, J.W. (2002) Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development. Breast Cancer Res., 4(4), 155-164.
15. Surowiak, P.; Suchocki, S.; Györffy, B.; Gansukh, T.; Wojnar, A.; Maciejczyk, A.; Pude..ko, M. and Zabel, M. (2006) Stromal myofibroblasts in breast cancer: relations between their occurrence, tumor grade and expression of some tumour markers. Folia Histochem. Cytobiol., 44(2), 111-116.
16. Kellermann, M.G.; Sobral, L.M.; da Silva, S.D.; Zecchin, K.G.; Graner, E.; Lopes, M.A.; Nishimoto, I.; Kowalski, L.P. and Coletta, R.D. (2007) Myofibroblasts in the stroma of oral squamous cell carcinoma are associated with poor prognosis. Histopathology, 51(6), 849-853.
17. Okawa, T.; Michaylira, C.Z.; Kalabis, J.; Stairs, D.B.; Nakagawa, H.; Andl, C.D.; Johnstone, C.; Klein-Szanto, A.J.; El-Deiry, W.S.; Cukierman, E.; Herlyn, M. and Rustgi, A.K. (2007) The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev., 21(21), 2788-2803.
18. Alexe, G.; Dalgin, G.S.; Scanfeld, D.; Tamayo, P.; Mesirov, J.P.; DeLisi, C.; Harris, L.; Barnard, N.; Martel, M.; Levine, A.J.; Ganesan, S. and Bhanot, G. 2007 High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res., 67(22), 10669-10676.
19. Hanahan, D. and Weinberg RA. (2000) The hallmarks of cancer. Cell, 100(1), 57-70.
20. Folkman, J. (1985) Tumor Angiogenesis. Adv. Cancer Res., 43, 175-203.
21. Mantovani, A.; Sozzani, S.; Locati, M.; Allavena, P. and Sica, A. (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol., 23(11), 549-555.
22. Lewis, C.E. and Pollard, J.W. (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res., 66(2), 605-612.
23. Balkwill, F. and Mantovani, A. (2001) Inflammation and cancer: back to Virchow? Lancet, 357(9255), 539-545.
24. Hotchkiss, K.A.; Ashton, A.W.; Klein, R.S.; Lenzi, M.L.; Zhu, G.H. and Schwartz, E.L. (2003) Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res., 63(2), 527-533.
25. Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364.
26. Ryschich, E.; Schmidt, J.; Hammerling, G.J.; Klar, E. and Ganss, R. (2002) Transformation of the microvascular system during multistage tumorigenesis. Int. J. Cancer, 97, 719-725.
27. Ryschich, E.; Lizdenis, P.; Ittrich, C.; Benner, A.; Stahl, S.; Hamann, A.; Schmidt, J.; Knolle, P.; Arnold, B.; Hammerling, G.J. and Ganss, R. (2006) Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepato-cellular carcinoma. Cancer Res., 66, 198-211.
28. Bergers, G.; Song, S.; Meyer-Morse, N.; Bergsland, E. and Hanahan, D. (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest., 111, 1287-1295.
29. Jain, R.K. and Booth, M.F. (2003) What brings pericytes to tumor vessels? J. Clin. Invest., 112(8), 1134-1136.
30. De Palma, M.; Venneri, M.A.; Galli, R.; Sergi Sergi, L.; Politi, L.S.; Sampaolesi, M. and Naldini, L. (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell, 8(3), 211-226.
31. Darland, D.C.; Massingham, L.J.; Smith, S.R.; Piek, E.; Saint-Geniez, M. and D'Amore, P.A. (2003) Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev. Biol., 264(1), 275-288.
32. Kale, S.; Hanai, J.; Chan, B.; Karihaloo, A.; Grotendorst, G.; Cantley, L. and Sukhatme, V.P. (2005) Microarray analysis of in vitro pericyte differentiation reveals an angiogenic program of gene expression. FASEB. J., 19(2), 270-271.
33. Morikawa, S.; Baluk, P.; Kaidoh, T.; Haskell, A.; Jain, R.K. and McDonald, D.M. (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol., 160(3), 985-1000.
34. Kalluri, R. and Zeisberg, M. (2006) Fibroblasts in cancer. Nat. Rev. Cancer, 6(5), 392-401.
35. Tuxhorn, J.A.; Ayala, G.E. and Rowley, D.R. (2001) Reactive stroma in prostate cancer progression. J. Urol., 166(6), 2472-2483.
36. Micke, P. and Ostman, A. (2004) Tumour-stroma interaction: cancer associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer, 45 (Suppl 2), S163-S175.
37. Mishra, P.J.; Mishra, P.J.; Humeniuk, R.; Medina, D.J.; Alexe, G.; Mesirov, J.P.; Ganesan, S.; Glod, J.W. and Banerjee, D. (2008) Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res., 68, 4331-4339.
38. Karnoub, A.E.; Dash, A.B.; Vo, A.P.; Sullivan, A.; Brooks, M.W.; Bell, G.W.; Richardson, A.L.; Polyak, K.; Tubo, R. and Weinberg, R.A. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449(7162), 557-563.
39. Jeon, E.S.; Moon, H.J.; Lee, M.J.; Song, H.Y.; Kim, Y.M.; Cho, M.; Suh, D.S.; Yoon, M.S.; Chang, C.L.; Jung, J.S. and Kim, J.H. (2008) Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells. Stem Cells, 26(3), 789-797.
40. Yoshida, S.; Ujiki, M.; Ding, X.Z.; Pelham, C.; Talamonti, M.S.; Bell, R.H. Jr.; Denham, W. and Adrian, T.E. (2005) Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs. Mol. Cancer, 4, 27.
41. Singer, C.F.; Kronsteiner, N.; Marton, E.; Kubista, M.; Cullen, K.J.; Hirtenlehner, K.; Seifert, M. and Kubista, E. (2002) MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res. Treat., 72(1), 69-77.
42. Sternlicht, M.D. and Bergers, G. (2000) Matrix metalloproteinases as emerging targets in anticancer therapy: Status and prospects. Emerg. Ther. Targets, 4, 609-633.
43. Sternlicht, M.D. and Werb, Z. (2001) How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol., 7, 463-516.
44. Boire, A.; Covic, L.; Agarwal, A.; Jacques, S.; Sherifi, S. and Kuliopulos, A. (2005) PAR1 is a matrix metalloproteinase-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell, 120, 303-313.
45. Lochter, A.; Galosy, S.; Muschler, J.; Freedman, N.; Werb, Z. and Bissell, M.J. (1997) Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol., 139, 1861-1872.
46. Ramos-DeSimone, N.; Hahn-Dantona, E.; Sipley, J.; Nagase, H.; French, D.L. and Quigley, J.P. (1999) Activation of matrix metalloproteinase 9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem., 274, 13066-13076.
47. Orimo, A.; Gupta, P.B.; Sgroi, D.C.; Arenzana-Seisdedos, F.; Delaunay, T.; Naeem, R.; Carey, V.J.; Richardson, A.L. and Weinberg, R.A. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 121(3), 335-348.
48. Chen, Y.; Stamatoyannopoulos, G. and Song, C.Z. (2003) Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res., 63(16), 4801-4.
49. Duffy, M.J. (2004) The urokinase plasminogen activator system: role in malignancy. Curr. Pharm. Des., 10(1), 39-49.
50. Han, B.; Nakamura, M.; Mori, I.; Nakamura, Y.; Kakudo, K. (2005) Urokinase-type plasminogen activator system and breast cancer (Review). Oncol. Rep., 14(1), 105-112.
51. Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D.; Moorman, M.A.; Simonetti, D.W.; Craig, S. and Marshak, D.R. (1999) Multilineage potential of adult human mesenchymal stem cells. Science, 284(5411), 143-147.
52. Menon, L.G.; Picinich, S.; Koneru, R.; Gao, H.; Lin, S.Y.; Koneru, M.; Mayer-Kuckuk, P.; Glod, J. and Banerjee, D. (2007) Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells, 25(2), 520-528.
53. Yashiro, M.; Ikeda, K.; Tendo, M.; Ishikawa, T. and Hirakawa, K. (2005) Effect of organ-specific fibroblasts on proliferation and differentiation of breast cancer cells. Breast Cancer Res. Treat., 90(3), 307-313.
54. Nakamizo, A.; Marini, F.; Amano, T.; Khan, A.; Studeny, M.; Gumin, J.; Chen, J.; Hentschel, S.; Vecil, G.; Dembinski, J.; Andreeff, M. and Lang, F.F. (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res., 65(8), 3307-3318.
55. Müller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M.E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S.N.; Barrera, J.L.; Mohar, A.; Verastegui, E. and Zlotnik, A. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature, 410(6824), 50-56.
56. Lin, E.Y.; Nguyen, A.V.; Russell, R.G.and Pollard, J.W. (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med., 193(6), 727-740.
57. Kim, K.U.; Wilson, S.M.; Abayasiriwardana, K.S.; Collins, R.; Fjellbirkeland, L.; Xu, Z.; Jablons, D.M.; Nishimura, S.L. and Broaddus, V.C. (2005) A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am. J. Resp. Cell Mol. Biol., 33(6), 541-548.
58. Müerköster, S.; Wegehenkel, K.; Arlt, A.; Witt, M.; Sipos, B.; Kruse, M.L.; Sebens, T.; Klöppel, G.; Kalthoff, H.; Fölsch, U.R. and Schäfer, H. (2004) Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res., 64(4), 1331-1337.
59. Connolly, D.T.; Heuvelman, D.M.; Nelson, R.; Olander, J.V.; Eppley, B.L. and Delfino, J.J. (1989) Tumour vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest., 84, 1470-1478.
60. Philips, G.D.; Stone, A.M.; Jones, B.D.; Schultz, J.C.; Whitehead, R.A. (1995) Vascular endothelial growth factor (rhVEGF 165) stimulates direct angiogenesis in the rabbit cornea. In Vivo, 8, 964-970.
61. Eatock, M.M.; Schätzlein, A. and Kaye, S.B. (2000) Tumour vasculature as a target for anticancer therapy. Cancer Treat. Rev., 26(3), 191-204.
62. Hofmeister, V.; Schrama, D. and Becker, J.C. (2008) Anti-cancer therapies targeting the tumor stroma. Cancer Immunol. Immunother., 57(1), 1-17.
63. Roboz, G.J.; Giles, F.J.; List, A.F.; Cortes, J.E.; Carlin, R.; Kowalski, M.; Bilic, S.; Masson, E.; Rosamilia, M.; Schuster, M.W.; Laurent, D. and Feldman, E.J. (2006) Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia, 20(6), 952-957.
64. Huss, W.J.; Barrios, R.J. Greenberg, N.M. (2003) SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis. Mol. Cancer Ther., 2(7), 611-616.
65. Lu, C.; Kamat, A.A.; Lin, Y.G.; Merritt, W.M.; Landen, C.N.; Kim, T.J.; Spannuth, W.; Arumugam, T.; Han, L.Y.; Jennings, N.B.; Logsdon, C.; Jaffe, R.B.; Coleman, R.L. and Sood, A.K. (2007) Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin. Cancer Res., 13(14), 4209-4217.
66. Desmoulière, A.; Guyot, C. and Gabbiani, G. (2004) The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int. J. Dev. Biol., 48(5-6), 509-517.
67. Bouzin, C. and Feron, O. (2007) Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist. Updat., 10(3), 109-120.
68. Pietras, K.; Rubin, K.; Sjöblom, T.; Buchdunger, E.; Sjöquist, M.; Heldin, C.H.; Ostman, A. (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res., 62(19), 5476-5484.
69. Scanlan, M.J.; Raj, B.K.; Calvo, B.; Garin-Chesa, P.; Sanz-Moncasi, M.P.; Healey, J.H.; Old, L.J.; Rettig, W.J. (1994) Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. USA, 91(12), 5657-5661.
70. Loeffler, M.; Krüger, J.A.; Niethammer, A.G.; Reisfeld, R.A. (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest., 116(7), 1955-1962.
71. Leek, R.D.; Hunt, N.C.; Landers, R.J.; Lewis, C.E.; Royds, J.A.; Harris, A.L. (2000) Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J. Pathol., 190(4), 430-436.
72. Skobe, M.; Hamberg, L.M.; Hawighorst, T.; Schirner, M.; Wolf, G.L.; Alitalo, K.; Detmar, M. (2001) Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am. J. Pathol., 159(3), 893-903.
73. Byrne, S.N.; Knox, M.C.; Halliday, G.M. (2008) TGFbeta is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction. Immunol. Cell Biol., 86(1), 92-97.
74. Salnikov, A.V.; Heldin, N.E.; Stuhr, L.B.; Wiig, H.; Gerber, H.; Reed, R.K.; Rubin, K. (2006) Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. Int. J. Cancer, 119(12), 2795-2802.
75. Salnikov, A.V.; Roswall, P.; Sundberg, C.; Gardner, H.; Heldin, N.E.; Rubin, K. (2005) Inhibition of TGF-beta modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab. Invest., 85(4), 512-521.
76. Zeisberger, S.M.; Odermatt, B.; Marty, C.; Zehnder-Fjällman, A.H.; Ballmer-Hofer, K.; Schwendener, R.A. (2006) Clodronateliposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer, 95(3), 272-281.
77. Luo, Y.; Zhou, H.; Krueger, J.; Kaplan, C.; Lee, S.H.; Dolman, C.; Markowitz, D.; Wu, W.; Liu, C.; Reisfeld, R.A.; Xiang, R. (2006) Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest., 116(8): 2132-2141.
78. Kelly T. (2005) Fibroblast activation protein-α and dipeptidyl peptidase IV (CD26), cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist. Updat., 8(1-2), 51-58.
79. Zhu, A.X.; Blaszkowsky, L.S.; Ryan, D.P.; Clark, J.W.; Muzikansky, A.; Horgan, K.; Sheehan, S.; Hale, K.E.; Enzinger, P.C.; Bhargava, P.; Stuart, K. (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol., 24: 1898-1903.
80. Belotti, D.; Calcagno, C.; Garofalo, A.; Caronia, D.; Riccardi, E.; Giavazzi, R.; Taraboletti, G. (2008) Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol. Cancer Res., 6(4), 525-534.
81. Karp, J.E.; Gojo, I.; Pili, R.; Gocke, C.D.; Greer, J.; Guo, C.; Qian, D.; Morris, L.; Tidwell, M.; Chen, H.; Zwiebel, J. (2004) Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabino-furanosyl-cytosine, mitoxantrone, and bevacizumab. Clin. Cancer Res., 10(11), 3577-3585.
82. Di Costanzo, F.; Mazzoni, F.; Micol Mela, M.; Antonuzzo, L.; Checcacci, D.; Saggese, M.; Di Costanzo, F. (2008) Bevacizumab in non-small cell lung cancer. Drugs, 68(6), 737-46.
83. Serruys, P.W.; Heyndrickx, G.R.; Patel, J.; Cummins, P.A.; Kleijne, J.A.; Clowes, A.W. (2003) Effect of an anti-PDGF-betareceptor-blocking antibody on restenosis in patients undergoing elective stent placement. Int. J. Cardiovasc. Intervent., 5(4), 214-222.
84. Jayson, G.C.; Parker, G.J.; Mullamitha, S.; Valle, J.W.; Saunders, M.; Broughton, L.; Lawrance, J.; Carrington, B.; Roberts, C.; Issa, B.; Buckley, D.L.; Cheung, S.; Davies, K.; Watson, Y.; Zinkewich-Péotti, K.; Rolfe, L.; Jackson, A. (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PE-Gylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J. Clin. Oncol., 23(5), 973-981.
85. Sparano, J.A.; Bernardo, P.; Stephenson, P.; Gradishar, W.J.; Ingle, J.N.; Zucker, S.; Davidson, N.E. (2004) Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group Trial E2196. J. Clin. Oncol., 22: 4683-4690.
86. Levin, V.A.; Phuphanich, S.; Yung, W.K.; Forsyth, P.A.; Maestro, R.D.; Perry, J.R.; Fuller, G.N.; Baillet, M. (2006) Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J. Neurooncol., 78(3), 295-302.
87. Bramhall, S.R.; Schulz, J.; Nemunaitis, J.; Brown, P.D.; Baillet, M.; Buckels, J.A. (2002) A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Can., 87: 161-167.
88. Hirte, H.; Vergote, I.B.; Jeffrey, J.R.; Grimshaw, R.N.; Coppieters, S.; Schwartz, B.; Tu, D.; Sadura, A.; Brundage, M.; Seymour, L. (2006) A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol. Oncol., 102(2), 300-308.
89. Saif, M.W. (2006) Anti-angiogenesis therapy in pancreatic carcinoma. JOP, 7(2), 163-173.
90. Bissett, D.; O'Byrne, K.J.; von Pawel, J.; Gatzemeier, U.; Price, A.; Nicolson, M.; Mercier, R.; Mazabel, E.; Penning, C.; Zhang, M.H.; Collier, M.A.; Shepherd, F.A. (2005) Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J. Clin. Oncol., 23(4), 842-849.
91. Heath, E.I.; Burtness, B.A.; Kleinberg, L.; Salem, R.R.; Yang, S.C.; Heitmiller, R.F.; Canto, M.I.; Knisely, J.P.; Topazian, M.; Montgomery, E.; Tsottles, N.; Pithavala, Y.; Rohmiller, B.; Collier, M.; Forastiere, A.A. (2006) Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest. New Drugs, 24(2), 135-140.
92. Ferrario, A.; Chantrain, C.F.; von Tiehl, K.; Buckley, S.; Rucker, N.; Shalinsky, D.R.; Shimada, H.; DeClerck, Y.A.; Gomer, C.J. (2004) The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res., 64(7), 2328-2332.
93. Weidenaar, A.C.; de Jonge, H.J.; Fidler, V.; ter Elst, A.; Meeuwsen-de Boer, T.; Douwes, J.; Bouma-ter Steege, J.C.; Hählen, K.; Kamps, W.A.; de Bont, E.S. (2008) Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death. Anticancer Drugs, 19(1), 45-54.
94. Joensuu, H.; De Braud, F.; Coco, P.; De Pas, T.; Putzu, C.; Spreafico, C.; Bono, P.; Bosselli, S.; Jalava, T.; Laurent, D.; Casali, P.G. (2008) Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann. Oncol., 19(1), 173-177.
95. Klenke, F.M.; Abdollahi, A.; Bertl, E.; Gebhard, M.M.; Ewerbeck, V.; Huber, P.E.; Sckell, A. (2007) Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer, 7: 49.
96. Naumova, E.; Ubezio, P.; Garofalo, A.; Borsotti, P.; Cassis, L.; Riccardi, E.; Scanziani, E.; Eccles, S.A.; Bani, M.R.; Giavazzi, R. (2006) The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin. Cancer Res., 12(6), 1839-1849.
97. Hofheinz, R.D.; al-Batran, S.E.; Hartmann, F.; Hartung, G.; Jäger, D.; Renner, C.; Tanswell. P.; Kunz, U.; Amelsberg, A.; Kuthan, H.; Stehle, G. (2003) Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie, 26(1), 44-48.
98. Scott, A.M.; Wiseman, G.; Welt, S.; Adjei, A.; Lee, F.T.; Hopkins, W.; Divgi, C.R.; Hanson, L.H.; Mitchell, P.; Gansen, D.N.; Larson, S.M.; Ingle, J.N.; Hoffman, E.W.; Tanswell, P.; Ritter, G.; Cohen, L.S.; Bette, P.; Arvay, L.; Amelsberg, A.; Vlock, D.; Rettig, W.J.; Old, L.J. (2003) A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9(5), 1639-1647.